BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Acute myeloid leukemia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for acute myeloid leukemia: 197 (136 sponsors; 27 newly posted in the last 180 days, 19 stopped in the last 180 days; 15 new-entrant sponsors). Momentum score 2.8, rank 91 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 83, Phase 2 64, Phase 3 25, Phase 4 4, N/A 18.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AbbVie ABBV | 10 | NA 2, P3 3, P4 2, P2 2, P1 1 | 0 | 1 |
| Actinium Pharmaceuticals ATNM | 2 | P3 2 | 0 | 0 |
| Kura Oncology, Inc. KURA | 5 | P1 3, P3 1, P2 1 | 1 | 1 |
| Taiho Oncology, Inc. | 5 | P2 2, P3 1, P1 2 | 0 | 2 |
| Janssen Research & Development, LLC | 4 | P1 3, P3 1 | 0 | 0 |
| Orca Biosystems, Inc. | 4 | P3 1, P2 1, P1 2 | 0 | 0 |
| Syndax Pharmaceuticals SNDX | 4 | P3 1, P1 2, P2 1 | 1 | 1 |
| Ascentage Pharma Group Inc. AAPG | 3 | P1 1, P2 1, P3 1 | 0 | 0 |
| Daiichi Sankyo | 3 | P2 2, P3 1 | 0 | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 3 | P1 2, P3 1 | 0 | 1 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 2 | P3 1, P1 1 | 1 | 0 |
| Sellas Life Sciences Group SLS | 2 | P3 1, P2 1 | 0 | 1 |
| Shijiazhuang Yiling Pharmaceutical Co. Ltd | 2 | P3 1, P1 1 | 0 | 0 |
| Sunshine Lake Pharma Co., Ltd. SBFM | 2 | P3 1, P2 1 | 0 | 0 |
| Hutchmed HCM | 1 | P3 1 | 0 | 0 |
| Ipsen new entrant | 1 | P3 1 | 1 | 0 |
| Moleculin Biotech, Inc. MBRX | 1 | P3 1 | 0 | 0 |
| Otsuka Australia Pharmaceutical Pty Ltd | 1 | P3 1 | 0 | 0 |
| Priothera SAS | 1 | P3 1 | 0 | 1 |
| Quetzal Therapeutics | 1 | P3 1 | 0 | 1 |
| SDK Therapeutics, Inc. | 1 | P3 1 | 0 | 0 |
| Servier Affaires Médicales | 1 | P3 1 | 0 | 0 |
| Bristol-Myers Squibb BMY | 3 | P2 2, NA 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 3 | P2 1, P1 1, P4 1 | 0 | 0 |
| OncoVerity, Inc. | 3 | P2 2, P1 1 | 0 | 2 |
New-entrant sponsors: Ipsen.
Recently stopped trials
- NCT06508489 Sanofi - terminated: Early discontinuation based on strategic sponsor decision not driven by any safety concerns A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological
- NCT05291390 Armaceutica, Inc. - suspended: Change of protocol Pyronaridine in Acute Myeloid Leukemia (AML)
- NCT05144334 Biotheryx, Inc. - terminated: Business decision A Study of BTX-1188 in Subjects With Advanced Malignancies
- NCT06679582 Sutro Biopharma, Inc. - terminated: Terminated Early Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
- NCT06419634 Bristol-Myers Squibb - terminated: Inability to meet protocol objectives Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Par
- NCT06541405 Base Therapeutics (Shanghai) Co., Ltd. - terminated: poor accrual Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
- NCT06541444 Base Therapeutics (Shanghai) Co., Ltd. - terminated: poor accrual Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
- NCT05424562 AbbVie - terminated: Strategic Considerations A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensi
- NCT05886491 Takeda - terminated: Sponsor decision (No safety concern) A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
- NCT06714591 SystImmune Inc. - terminated: Sponsor prioritization of other development portfolio Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
- NCT04021368 Ryvu Therapeutics SA - terminated: RPD2 has been identified RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
- NCT06268574 Ryvu Therapeutics SA - terminated: Sponsor decision Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
- NCT06704152 BlueSphere Bio, Inc - terminated: Company Decision BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
- NCT07566585 BlueSphere Bio, Inc - withdrawn: Company Decision Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients Wi
- NCT05086315 Sanofi - terminated: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractor
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | Institut de Recherches Internationales Servier (I.R.I.S.) | NCT06052813 A Study of BN104 in the Treatment of Acute Leukemia | ALL, Adult; AML, Adult; Acute Leukaemia; KMT2A Rearrangement; NPM1 Mutation; NUP98 Gene Rearrangemen | active not recruiting | 66 |
| 2026-12 est. | P2 | Ryvu Therapeutics SA | NCT06987058 RVU120 Rollover Study | Advanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndrome | enrolling by invitation | 14 |
| 2027-02 est. | P1/P2 | AbbVie ABBV | NCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Acute Myeloid Leukemia | active not recruiting | 218 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P1/P2 | Aptose Biosciences Inc. | NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute | Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess B | recruiting | 240 |
| 2026-09-08 | P1/P2 | BlueSphere Bio, Inc | NCT06704152 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | AML, Adult Recurrent; ALL, Recurrent, Adult; MDS | terminated | 2 |
| 2026-08 est. | P1/P2 | AB Science | NCT05211570 AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acut | recruiting | 78 |
| 2026-07-14 | P1/P2 | Ossium Health, Inc. | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malign | Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; A | active not recruiting | 12 |
| 2026-06-20 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma | unknown | 312 |
| 2026-06 est. | P1/P2 | Advanced BioDesign | NCT05601726 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AM | Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes | recruiting | 36 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "acute myeloid leukemia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.